General Atlantic Invests in LePure Biotech

Paul, Weiss advised General Atlantic in its Series C investment in Shanghai LePure Biotech Co., Ltd. (LePure Biotech), a China-based single-use solutions provider for biopharmaceutical companies. General Atlantic co-led the funding round alongside Novo Holdings and Goldman Sachs Asset Management, with participation from existing investors including Highlight Capital, Bayland Capital and HM Capital. Financial terms of the transaction were not disclosed.

LePure will use the funding to accelerate product innovation, promote overseas expansion and enhance the company’s competitiveness and influence in the global industrial chain.

The Paul, Weiss team included corporate partner Judie Ng Shortell and counsel Jack Sun; tax partner Lindsay Parks; antitrust counsel Marta Kelly; and international trade counsel Richard Elliott.